At the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases in Munich, Shionogi presented data from the CIRCE study that should change how we talk about antimicrobial resistance. Cefiderocol, marketed as Fetroja and Fetcroja, achieved a 68% clinical cure rate at day 14 in patients infected with metallo-beta-lactamase-producing Enterobacterales. At day 28, 83% of patients were alive.
These patients were not mildly ill. At baseline, 29% were immunosuppressed. Twenty-seven percent were in intensive care. Thirteen percent presented with septic shock. The infections they carried resisted every other antibiotic class available. Cefiderocol worked where nothing else did. That is what a siderophore cephalosporin does: it tricks bacteria into absorbing it by mimicking iron, the nutrient they need to survive. The mechanism is elegant. The results are concrete.
The CIRCE study was retrospective and observational, conducted across multiple hospitals in Spain between January 2023 and April 2025, covering 232 adult patients. An 82% positive clinical response rate at day 14 accompanied the cure data. No new safety signals emerged beyond cefiderocol's established profile. Real-world evidence from the sickest patients, in ordinary hospital settings, with results that held.
CIRCE Study Results: 68% clinical cure at day 14, 82% positive clinical response, and 83% survival at day 28 in MBL-producing Enterobacterales infections.
Verified
Antimicrobial resistance kills 1.27 million people each year, according to the Lancet's 2022 global burden study. By 2050, projections estimate 10 million annual deaths if resistance trends continue unchecked. These numbers have circulated for years. Policy responses remain inadequate. The global antibiotic pipeline contains fewer than 80 candidates, compared to over 6,000 oncology drugs in development.
Bipi NewsReal-Time, Evidence-Based News Reports
Unlimited access to your personalized investigative reporter agent, sourcing real-time and verified reports on any topic. Your personalized news feed starts here.
Create Free AccountThe market failure is well documented. Antibiotics are used for short courses, priced low, and succeed when they make themselves unnecessary. Pharma companies earn more from chronic disease drugs prescribed for decades. Shionogi is one of the few major companies that maintained its antimicrobial research program. The company ranked second globally in the 2026 Antimicrobial Resistance Benchmark, an acknowledgment that most of its peers abandoned the field.
Patient Severity: 29% immunosuppressed, 27% in ICU, 13% in septic shock at baseline across 232 patients in Spanish hospitals.
Verified
Cefiderocol received FDA approval in 2019 for complicated urinary tract infections and expanded indications for hospital-acquired pneumonia. China approved the drug in January 2026. Each approval expands access. But approval is not the same as availability. In low- and middle-income countries where resistant infections kill the most people, access to novel antibiotics remains constrained by pricing, supply chains, and regulatory lag.
The 68% cure rate proves something broader than cefiderocol's efficacy. It proves that antimicrobial resistance is a problem with available solutions. Researchers can design molecules that defeat resistant bacteria. Clinicians can deploy them in real-world settings with meaningful outcomes. The obstacle is not scientific. It is structural. Funding, incentives, and distribution systems determine who lives and who dies from treatable infections.
AMR Death Toll: 1.27 million annual deaths from antimicrobial resistance, projected to reach 10 million by 2050.
Verified
Bipi NewsThink Further on BIPI.
Where seeking the truth is a journey, not a destination.
Learn morePull incentives could change the economics. The UK's subscription model pays pharmaceutical companies a fixed annual fee for access to novel antibiotics, regardless of volume used. The PASTEUR Act in the US Congress proposed similar mechanisms but stalled. These are solvable policy problems. The UK model is running. The data is coming in. Other countries could adopt it within a legislative session if the political will existed.
Every right we take for granted was once called impossible. The right to survive a bacterial infection, established when penicillin reached mass production in 1944, is now eroding. Resistance reclaims ground that science won 80 years ago. Cefiderocol pushes back. But one drug from one company treating one class of resistant bacteria is not a strategy. It is a proof of concept waiting for a system that matches its ambition.
Pipeline Gap: Fewer than 80 antibiotic candidates in development globally, compared to 6,000+ oncology drugs.
Verified
The patients in the CIRCE study had no other options. Cefiderocol gave 68% of them their health back and kept 83% of them alive at four weeks. Scaling that result requires investment on the order of what we give cancer research, distribution infrastructure that reaches hospitals in sub-Saharan Africa and South Asia, and regulatory frameworks that reward companies for developing drugs the world needs rather than drugs the market wants. The science works. The question is whether we build the system to deliver it.